

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.

This announcement is not a prospectus. Potential investors should read the prospectus dated October 28, 2025 (the “**Prospectus**”) issued by Vigonvita Life Sciences Co., Ltd. (蘇州旺山旺水生物醫藥股份有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

This announcement is made by the Company pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).



Vigonvita Life Sciences Co., Ltd.

蘇州旺山旺水生物醫藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2630)

END OF STABILIZATION PERIOD, NO STABILIZING ACTIONS AND LAPSE OF OVER-ALLOTMENT OPTION

This announcement is made by the Company pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on December 3, 2025, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

NO STABILIZING ACTIONS AND LAPSE OF OVER-ALLOTMENT OPTION

Reference is made to the announcement of final Offer Price and allotment results of the Company dated November 5, 2025. There was no over-allocation of H Shares in the International Offering. No stabilizing actions were undertaken by the Stabilizing Manager or any person acting for it during the stabilization period. The Sponsor-Overall Coordinator (for itself and on behalf of the International Underwriters) did not exercise the Over-allotment Option, which lapsed on December 3, 2025. Accordingly, no H Shares were or will be issued by the Company under the Over-allotment Option.

PUBLIC FLOAT

Immediately after the end of the stabilization period, the Company complies and will continue to comply with the public float requirement under Rule 19A.13A of the Listing Rules.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
*Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager*

Hong Kong, December 3, 2025

As of the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.